# A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

> **NCT00658567** · PHASE3 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 123 (actual)

## Conditions studied

- Parkinson's Disease Psychosis

## Interventions

- **DRUG:** Pimavanserin tartrate (ACP-103)
- **DRUG:** Pimavanserin tartrate (ACP-103)
- **DRUG:** Pimavanserin tartrate (ACP-103)

## Key facts

- **NCT ID:** NCT00658567
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658567, "A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00658567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*